SparingVision to buy GAMUT and potential Luxturna eye gene therapy competitorFrench genomic medicines firm SparingVision has agreed to buy GAMUT Therapeutics, a biotech specialising in gene therapies for Share XSparingVision to buy GAMUT and potential Luxturna eye gene therapy competitorhttps://pharmaphorum.com/news/sparingvision-to-buy-gamut-and-potential-luxturna-gene-therapy-competitor/
UK Vaccine Taskforce head lifts lid on Novavax dealThe UK’s unique offering as a life sciences research hub helped convince US biotech Novavax to develop its Share XUK Vaccine Taskforce head lifts lid on Novavax dealhttps://pharmaphorum.com/news/novavax-developed-vaccine-in-uk-because-of-rd-opportunities/
Risk of brain clots higher with COVID than vaccine, study suggestsA study has suggested that the risk of getting a serious brain clot is eight to 10 times Share XRisk of brain clots higher with COVID than vaccine, study suggestshttps://pharmaphorum.com/news/risk-of-brain-clots-higher-with-covid-than-vaccine-study-suggests/
Magic mushroom compound matches antidepressant in clinical trialThe active compound in magic mushrooms – psilocybin – seems to be at least as effective as a Share XMagic mushroom compound matches antidepressant in clinical trialhttps://pharmaphorum.com/news/magic-mushroom-compound-matches-antidepressant-in-clinical-trial/
Activist investor Elliott builds stake in GSK after fresh trial upsetActivist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial Share XActivist investor Elliott builds stake in GSK after fresh trial upsethttps://pharmaphorum.com/news/activist-investor-elliott-builds-stake-in-gsk-after-fresh-trial-upset/
Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says RocheRoche’s Genentech unit has released further data from a key trial of Evrysdi, its oral treatment for spinal Share XEvrysdi has ‘real world impact’ on lives of babies with severe SMA, says Rochehttps://pharmaphorum.com/news/evrysdi-has-real-world-impact-on-lives-of-babies-with-severe-sma-says-roche/
Romark eyes FDA okay for COVID antiviral despite mixed trial resultsA phase 3 trial of Romark’s antiviral drug NT-300 has missed the main objective in a phase 3 Share XRomark eyes FDA okay for COVID antiviral despite mixed trial resultshttps://pharmaphorum.com/news/romark-eyes-fda-okay-for-covid-antiviral-despite-mixed-trial-results/
Pfizer/Myovant take relugolix contraceptive combination pill into phase 3Pfizer and Myovant have begun a late-stage trial of their potential uterine fibroid drug relugolix, as part of Share XPfizer/Myovant take relugolix contraceptive combination pill into phase 3https://pharmaphorum.com/news/pfizer-myovant-take-relugolix-contraceptive-combination-pill-into-phase-3/
Race for hepatitis B drug intensifies as Antios raises $96m for phase 2 trialAntios has raised $96 million in Series B financing to support the ongoing phase 2 development of its Share XRace for hepatitis B drug intensifies as Antios raises $96m for phase 2 trialhttps://pharmaphorum.com/news/race-for-hepatitis-b-drug-intensifies-as-antios-raises-96m-for-phase-2-trial/
